Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNXNASDAQ:EGRXNASDAQ:MIRMNASDAQ:RLMDNASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$29.88+1.5%$31.21$24.10▼$62.53$2.80B0.25816,069 shs461,098 shsEGRXEagle Pharmaceuticals$3.00+3.6%$2.21$1.50▼$3.00$38.96M0.838,193 shs620 shsMIRMMirum Pharmaceuticals$49.93+1.7%$46.46$34.47▼$54.23$2.47B0.97462,684 shs216,684 shsRLMDRelmada Therapeutics$0.63+4.3%$0.58$0.24▼$4.47$20.81M0.59972,728 shs297,692 shsSIGASiga Technologies$6.74+0.8%$6.09$4.95▼$12.83$481.15M0.94718,017 shs209,179 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals0.00%-0.28%-9.50%+13.25%-31.84%EGRXEagle Pharmaceuticals0.00%+3.45%+33.33%+62.16%-45.45%MIRMMirum Pharmaceuticals0.00%-2.27%+7.65%+21.78%+45.02%RLMDRelmada Therapeutics0.00%+2.79%-24.90%+141.06%-79.24%SIGASiga Technologies0.00%+4.26%+11.69%+26.36%-12.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRNXCrinetics Pharmaceuticals3.3027 of 5 stars3.50.00.03.71.12.50.0EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals3.9015 of 5 stars3.60.00.04.22.02.50.6RLMDRelmada Therapeutics4.6153 of 5 stars3.15.00.04.40.04.21.3SIGASiga Technologies0.8766 of 5 stars0.01.00.00.00.00.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.90Moderate Buy$71.75140.17% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AMIRMMirum Pharmaceuticals 3.13Buy$65.5031.18% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00697.45% UpsideSIGASiga Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EGRX, SIGA, RLMD, CRNX, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M2,689.61N/AN/A$14.29 per share2.09EGRXEagle Pharmaceuticals$257.55M0.15$7.50 per share0.40N/A∞MIRMMirum Pharmaceuticals$336.89M7.34N/AN/A$4.70 per share10.62RLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ASIGASiga Technologies$138.72M3.47$0.84 per share7.99$3.02 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.51N/AN/AN/AN/A-181.26%-151.23%8/6/2025 (Estimated)SIGASiga Technologies$59.21M$0.6710.055.39N/A40.30%25.21%22.05%7/30/2025 (Estimated)Latest EGRX, SIGA, RLMD, CRNX, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million5/8/2025Q1 2025SIGASiga TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ALatest EGRX, SIGA, RLMD, CRNX, and MIRM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/8/2025SIGASiga Technologiesspecial$0.604/29/20254/29/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A22.5322.53EGRXEagle PharmaceuticalsN/AN/AN/AMIRMMirum Pharmaceuticals1.323.223.04RLMDRelmada TherapeuticsN/A5.295.29SIGASiga TechnologiesN/A8.406.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%EGRXEagle Pharmaceuticals85.36%MIRMMirum PharmaceuticalsN/ARLMDRelmada Therapeutics45.24%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals6.00%EGRXEagle Pharmaceuticals28.90%MIRMMirum Pharmaceuticals22.87%RLMDRelmada Therapeutics20.70%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21093.63 million88.01 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataMIRMMirum Pharmaceuticals14049.53 million38.21 millionOptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableSIGASiga Technologies4071.44 million70.05 millionOptionableEGRX, SIGA, RLMD, CRNX, and MIRM HeadlinesRecent News About These CompaniesWhy Siga Technologies Inc. (SIGA) Outpaced the Stock Market TodayJune 26, 2025 | zacks.comInvestors Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)June 26, 2025 | marketbeat.comNew nuclear fuel cladding survive 3,452°F, 6 times hotter than normal reactorsJune 25, 2025 | msn.comGeneral Atomics Achieves Another Milestone in Silicon Carbide Composite Nuclear Fuel Rod TechnologyJune 24, 2025 | indystar.comIHere's Why Siga Technologies Inc. (SIGA) Fell More Than Broader MarketJune 20, 2025 | zacks.comUndiscovered Gems In US Market Including SIGA Technologies And 2 Other Small CapsJune 17, 2025 | finance.yahoo.comBank of America Corp DE Sells 367,682 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)June 16, 2025 | marketbeat.comWhy Siga Technologies Inc. (SIGA) Dipped More Than Broader Market TodayJune 13, 2025 | zacks.comSIGA Technologies, Inc. (NASDAQ:SIGA) Shares Bought by Harbor Capital Advisors Inc.June 13, 2025 | marketbeat.comTraders Buy High Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)June 12, 2025 | marketbeat.comWe Think You Can Look Beyond SIGA Technologies' (NASDAQ:SIGA) Lackluster EarningsMay 16, 2025 | finance.yahoo.comUndiscovered Gems in the US Market for May 2025May 15, 2025 | finance.yahoo.comSIGA Technologies First Quarter 2025 Earnings: US$0.006 loss per share (vs US$0.14 profit in 1Q 2024)May 10, 2025 | finance.yahoo.comSIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comSIGA Reports Financial Results for Three Months Ended March 31, 2025May 8, 2025 | globenewswire.comCalculating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)May 2, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Stock Declines While Market Improves: Some Information for InvestorsMay 1, 2025 | zacks.comSIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 ResultsMay 1, 2025 | globenewswire.comChiliz joins SIGA to help drive integrity in sportApril 30, 2025 | en.as.comEWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Down 11.34%April 29, 2025 | aaii.comAHere's Why Siga Technologies Inc. (SIGA) Gained But Lagged the Market TodayApril 25, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, SIGA, RLMD, CRNX, and MIRM Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$29.88 +0.44 (+1.48%) Closing price 07/3/2025 01:45 PM EasternExtended Trading$29.70 -0.17 (-0.57%) As of 08:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Eagle Pharmaceuticals NASDAQ:EGRX$3.00 +0.11 (+3.63%) As of 07/3/2025 09:30 AM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Mirum Pharmaceuticals NASDAQ:MIRM$49.93 +0.84 (+1.71%) Closing price 07/3/2025 02:30 PM EasternExtended Trading$49.85 -0.08 (-0.16%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Relmada Therapeutics NASDAQ:RLMD$0.63 +0.03 (+4.31%) Closing price 07/3/2025 02:38 PM EasternExtended Trading$0.63 +0.00 (+0.48%) As of 07:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.Siga Technologies NASDAQ:SIGA$6.74 +0.06 (+0.82%) Closing price 07/3/2025 03:40 PM EasternExtended Trading$6.72 -0.02 (-0.22%) As of 08:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story CAVA Group: Why the Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
